Pressemitteilung -
Hope for new Alzheimer's drug from Saxony-Anhalt
Probiodrug is pushing ahead with the development of its business in the United States
The biopharmaceutical company Probiodrug from Halle/Saale, Saxony-Anhalt, is researching new approaches into fighting Alzheimer's disease. Probiodrug has been listed on the Euronext stock exchange in Amsterdam since 2014. The company has successfully developed a new therapy concept for diabetics in the past.
Since 2007, no new drug has been approved for the treatment of Alzheimer's disease. The medical products currently available only treat the symptoms. "They improve the transmission of signals between the synapses. They don't prevent the neuronal decline, however," explains Konrad Glund. Glund is the co-founder and CEO of the biotechnology company Probiodrug which is based in Halle/Saale in the German federal state of Saxony-Anhalt, a location that the entrepreneur believes to provide excellent conditions for research and development. "The research conditions are very good and they have improved further in recent years. Saxony-Anhalt offers interesting financial instruments and provides start-up financing and investor mediation. It also provides direct project funding."
For more than twelve years, the company has been conducting research into a concept of therapy for treating Alzheimer's disease. The researchers from Saxony-Anhalt have discovered a mechanism through which a normal brain peptide, called amyloid-beta, is chemically changed and therefore advances the disease...
Click here to read the full article: http://lsaurl.de/probio16
---
Probiodrug is based in the German federal state of Saxony-Anhalt, a location that the company believes to provide excellent conditions for research and development and the right financial instruments. It is only one of several flagship companies representing Saxony-Anhalt's competence in biotechnology and pharmaceuticals at BIO International Convention 2016 in San Francisco.
Meet us at booth 1005-03, in the German Pavilion, at BIO 2016 and get to know Germany's biotech region Saxony-Anhalt.
Themen
- Medien, Kommunikation
Kategorien
- img
- sachsen-anhalt
- biotechnology
- probiodrug
- alzheimer
Regionen
- Sachsen-Anhalt
Background: IMG - Investment and Marketing Corporation Saxony-Anhalt
The Investment and Marketing Corporation Saxony-Anhalt mbH (IMG) is the business development agency of German federal state of Saxony-Anhalt.
It provides all services relating to company establishment in the state. These services – ranging from investor acquisition via business consulting trough to locating marketing for the business and science location as well as tourism marketing – are united under one roof.
As one-stop agency, commissioned by the Ministry of Sciences and Economic Affairs of Saxony-Anhalt, IMG supports companies in the realization of their investment project. IMG acts as partner for business, providing individually tailored consultancy in all matters - from finding a suitable site, information on subsidy and financing matters, to dealing with public authorities up to all matters concerning the realization of the settlement or investment.
Further information about our services you find here.
